ESC 365 - SGLT2 inhibitors and vericiguat in real-world patients admitted for worsening heart failure

ESC Professional Premium Access

SGLT2 inhibitors and vericiguat in real-world patients admitted for worsening heart failure

Session: Medical therapy for acute heart failure and changing outcomes

Topic: Pharmacotherapy

Speaker: Doctor R. Tarantini (Pavia, IT)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Roberto Tarantini

University of Pavia, Pavia (Italy)

1 follower

4 more presentations in this session

Impact of in-hospital initiation of sodium-glucose cotransporter-2 inhibitors in patients with heart failure and reduced ejection fraction

Speaker: Ms M. Diez (Buenos Aires, AR)

Evidence-based heart failure therapies at discharge of patients with acute coronary syndromes and reduced ejection fraction: Data from the ACSIS survey

Speaker: Doctor F. Bahouth (Nazareth, IL)

Association between sex and efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency: an AFFIRM-AHF subgroup analysis

Speaker: Professor G. Rosano (London, GB)

One-year outcomes in cardiogenic shock triggered by supraventricular tachycardia: an analysis of the FRENSHOCK multicenter prospective registry.

Speaker: Professor P. Maury (Toulouse, FR)

Access the full session

Medical therapy for acute heart failure and changing outcomes

Speakers: Doctor R. Tarantini, Ms M. Diez, Doctor F. Bahouth, Professor G. Rosano, Professor P. Maury

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by